Zura Bio Limited (NASDAQ:ZURA - Get Free Report) saw a significant increase in short interest during the month of November. As of November 15th, there was short interest totalling 4,960,000 shares, an increase of 183.4% from the October 31st total of 1,750,000 shares. Approximately 10.6% of the shares of the company are sold short. Based on an average daily trading volume, of 444,500 shares, the days-to-cover ratio is presently 11.2 days.
Insider Buying and Selling
In other Zura Bio news, Director Someit Sidhu sold 51,728 shares of the company's stock in a transaction dated Wednesday, September 4th. The stock was sold at an average price of $3.87, for a total value of $200,187.36. Following the completion of the sale, the director now owns 2,085,418 shares in the company, valued at $8,070,567.66. This represents a 2.42 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Parvinder Thiara sold 1,001,633 shares of Zura Bio stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $2.73, for a total value of $2,734,458.09. The disclosure for this sale can be found here. 22.10% of the stock is currently owned by insiders.
Institutional Trading of Zura Bio
Several hedge funds have recently modified their holdings of ZURA. AQR Capital Management LLC bought a new stake in Zura Bio in the second quarter worth $43,000. Healthcare of Ontario Pension Plan Trust Fund purchased a new position in shares of Zura Bio in the 3rd quarter worth $46,000. Renaissance Technologies LLC increased its holdings in shares of Zura Bio by 51.3% in the 2nd quarter. Renaissance Technologies LLC now owns 17,400 shares of the company's stock worth $61,000 after buying an additional 5,900 shares during the last quarter. SG Americas Securities LLC purchased a new stake in shares of Zura Bio during the 3rd quarter valued at about $62,000. Finally, Valence8 US LP bought a new position in shares of Zura Bio in the 3rd quarter valued at about $71,000. 61.14% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
A number of equities research analysts have commented on ZURA shares. Cantor Fitzgerald restated an "overweight" rating on shares of Zura Bio in a research note on Friday, October 18th. Piper Sandler restated an "overweight" rating and set a $26.00 price objective on shares of Zura Bio in a research report on Thursday, September 19th. Leerink Partnrs raised shares of Zura Bio to a "strong-buy" rating in a report on Monday, November 4th. HC Wainwright reiterated a "neutral" rating and issued a $5.00 price target on shares of Zura Bio in a research note on Monday, November 18th. Finally, Chardan Capital lowered their price objective on Zura Bio from $14.00 to $12.00 and set a "buy" rating on the stock in a research report on Friday, November 8th. One investment analyst has rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Buy" and a consensus target price of $15.80.
Check Out Our Latest Stock Report on Zura Bio
Zura Bio Stock Performance
NASDAQ ZURA traded down $0.01 on Thursday, reaching $3.00. The company had a trading volume of 252,387 shares, compared to its average volume of 327,489. Zura Bio has a 12 month low of $2.00 and a 12 month high of $6.35. The firm's 50 day moving average price is $4.09 and its 200 day moving average price is $4.02.
Zura Bio (NASDAQ:ZURA - Get Free Report) last issued its earnings results on Thursday, November 7th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.12). As a group, analysts anticipate that Zura Bio will post -0.65 EPS for the current fiscal year.
About Zura Bio
(
Get Free Report)
Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.
Recommended Stories
Before you consider Zura Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zura Bio wasn't on the list.
While Zura Bio currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
